T(
Therapeutic Areas
REGENXBIO Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RGX-121 | Mucopolysaccharidosis Type II (MPS II, Hunter syndrome) | Phase I/II/III |
| RGX-202 | Duchenne Muscular Dystrophy (DMD) | Phase I/II |
| RGX-381 | Ocular manifestations of FA (Cone-rod dystrophy) | Phase I/II |
| RGX-314 | Wet Age-related Macular Degeneration (AMD) | Phase II |
| ABBV-RGX-314 | Wet Age-related Macular Degeneration (AMD) | Phase III |
Leadership Team at REGENXBIO
KT
Kenneth T. Mills
President and Chief Executive Officer
OD
Olivier Danos, Ph.D.
Chief Scientific Officer
CP
Curran P. Simpson, Ph.D.
Chief Operating and Technical Officer
PJ
Patrick J. Christmas II
Chief Legal Officer and Corporate Secretary
P(
Piotr (Peter) W. Tarkowski, Ph.D.
Chief Financial Officer
JM
James M. Wilson, M.D., Ph.D.
Director, Head of Gene Therapy Program at UPenn (Scientific Founder)